1 |
IntraOmmaya compartmental radioimmunotherapy using 131 I-omburtamab-pharmacokinetic modeling to optimize therapeutic index. Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1166-1177.
|
2 |
Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapy. Cancer Immunol Immunother. 2021 Feb 3.
|
3 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
4 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
5 |
ClinicalTrials.gov (NCT05220098) A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer. U.S.National Institutes of Health.
|
6 |
Clinical pipeline report, company report or official report of Daiichi Sankyo.
|
7 |
Clinical pipeline report, company report or official report of MacroGenics.
|
8 |
National Cancer Institute Drug Dictionary (drug id 722029).
|
9 |
T Cell Coinhibition and Immunotherapy in Human Breast Cancer. Discov Med. 2012 October; 14(77): 229-236.
|
|
|
|
|
|
|